 | |
| Company type | Public (K.K) |
|---|---|
| Industry | Pharmaceutical |
| Predecessors | Yamanouchi Pharmaceutical Fujisawa Pharmaceutical (Merged in 2005) |
| Founded | 1 April 2005 |
| Headquarters | 2-5-1, Nihonbashi-Honcho, Chūō-ku, Tokyo 103-8411, Japan |
Key people | Naoki Okamura (President and CEO) Kenji Yasukawa (Chairman of the Board) |
| Products | |
| Revenue |  US$11.418 billion [1] (2023) |
 US$1 billion [1] (2023) | |
| US$0.742 billion [1] (2023) | |
| Total assets | US$18.47 billion [1] (2023) |
| Total equity | US$11.33 billion [1] (2023) |
Number of employees | 14,484[1] (2023) |
| Subsidiaries | Astellas US |
| Website | www.astellas.com/en/ |
| Footnotes / references [1] [2][3][4] | |
Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha).
Astellas is a member of the Mitsubishi UFJ Financial Group (MUFJ) keiretsu.
- ^ a b c d e f g "Astellas Pharma Financial Statements 2009-2024 | ALPMY". macrotrends.
- ^ "Corporate Profile". Astellas Pharma. Archived from the original on August 14, 2012. Retrieved September 9, 2014.
- ^ "Annual Report 2014" (PDF). Astellas Pharma. Archived from the original (PDF) on March 3, 2016. Retrieved September 9, 2014.
- ^ "Astellas Pharma Snapshot". Bloomberg Businessweek. Retrieved January 25, 2015.